Cover Image
市場調查報告書

全球治療癌症用單株抗體市場及開發中產品分析

Global Cancer Monoclonal Antibodies Market & Pipeline Insight

出版商 KuicK Research 商品編碼 315360
出版日期 內容資訊 英文 1400 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球治療癌症用單株抗體市場及開發中產品分析 Global Cancer Monoclonal Antibodies Market & Pipeline Insight
出版日期: 2014年10月01日 內容資訊: 英文 1400 Pages
簡介

近年來單株抗體領域相繼發現、改良出新產品,並拓展出具有便低毒性的有效替代性治療法之道。在這數牛年間人體免疫系統相關的研究不斷發展,關係到相關法規的改正及改善,治療癌症用單株抗體(mAB)也在急速擴大。各種研究開發的結果,發現單株抗體及放射/化學標籤抗體組合具有高度的延長壽命效果。活用單株抗體,進一步提升醫藥品安全性的這個趨勢也正在擴大。相信今後這個開發改良的動向也將持續下去。

本報告提供全球的治療癌症用單株抗體市場及開發中產品(開發中醫藥品)狀況相關分析,提供單株抗體的功能·工作機制和主要的種類,治療癌症方面單株抗體的實際成果,開發中產品的開發發展情形和可望的效果資訊,為您概述為以下內容。

第1章 單株抗體概要

  • 單株抗體的發展歷史
  • 單株抗體的功能

第2章 單株抗體的種類

  • 非修飾單株抗體
  • 複合型單株抗體
    • 輻射標識抗體(Radiolabeled Antibodies)
    • 化學標識抗體(Chemolabeled Antibodies)
    • 免疫毒素

第3章 單株抗體的機制

  • 腫瘤抗原這個抗體標的
  • 為求臨床目的的抗體開發
  • 補體依賴細胞障礙 (CDC)
  • 信號傳送的變化

第4章 癌症治療上單株抗體的必要性

第5章 癌症單株抗體市場概要

  • 目前市場方案
  • 臨床實驗平台的考察

第6章 癌症單株抗體市場動態

  • 良好的市場參數
  • 課題
  • 今後的成長預測

第7章 癌症單株抗體的開發中產品:代(階段),適應症,企業,國別

  • 階段不明
  • 研究階段
  • 藥物研發階段
  • 臨床階段
  • 第一階段
  • 第I/II代
  • 第II代
  • 第II/III代
  • 第III代
  • 認證中
  • 已認證

第8章 已上市的癌症單株抗體:各適應症·各企業·各國

第9章 臨床實驗中斷·中止的單株抗體開發中產品:不同階段:各適應症·各企業·各國

  • 未提出開發報告
  • 中止的
  • 退出市場的
  • 中斷的

第10章 競爭環境

  • Abbvie
  • Amgen
  • Bayer HealthCare
  • Biogen Idec
  • Eli Lilly
  • Genmab
  • Gilead Sciences
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Roche
  • Seattle Genetics

圖表一覽

目錄

Recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body's immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability of these agents has enabled the pharma companies to develop novel combination approaches which have the capability to provide even greater insight into the body's immune system so as to develop more efficient mAbs.

A significant amount of research is being carried out currently to improve the level of potency of monoclonal antibodies. Consequently, a relatively new approach has been indentified in which the precision of targeting molecules would be combined with the proved killing power of radiation or cytotoxic chemotherapy which is referred to as payload to precise molecular carriers, mostly monoclonal antibodies. However, still a lot of work needs to be done in this arena.

Though the monoclonal antibodies have already emerged as significant part of the treatment for many cancers, the use of these antibodies in other aspects of cancer treatment is yet to be tapped. In this regard, research is currently being undertaken to understand deeply the process and reason for cancer cells being different from normal cells and the use of mAbs to exploit these differences. This has led to the development of many newer forms of mAbs, which are being attached to drugs or other substances thus making them more powerful.

Additionally, the pharma companies are also researching on ways and means to make these drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high chance that these antibodies could possibly make the body's immune system react against them, which could result in many side effects, and also destruction of the mAbs. The newly developed forms of mAbs are a solution to this problem and are less likely to cause immune reactions.

It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer MAb targets would be successfully identified for regulating tumor cell growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic antibodies. The future of mAbs for cancer continues to be overflowing with huge potential as a result of an increasing number of new discoveries and techniques. Inspite of advances being made in terms of understanding of the complexities of the human cells there is still significant work which needs to be done.

"Global Cancer Monoclonal Antibodies Market & Pipeline Insight" Report highlights:

  • Cancer Monoclonal Antibodies Market Overview
  • Emerging Market Dynamics: Favorable Parameters, Challenges & Growth Outlook
  • Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country
  • Cancer Monoclonal Antibodies in Pipeline: 605
  • Majority Cancer Monoclonal Antibodies Preclinical Phase: 258
  • Marketed Cancer Monoclonal Antibodies: 34
  • Cancer Monoclonal Antibodies Patent Analysis

Table of Contents

1. Introduction to Monoclonal Antibodies

  • 1.1 History of Development of Monoclonal Antibodies
  • 1.2 Working of Monoclonal Antibodies

2. Types of Monoclonal Antibodies

  • 2.1 Naked Monoclonal Antibodies
  • 2.2 Conjugated Monoclonal Antibodies
    • 2.2.1 Radiolabeled Antibodies
    • 2.2.2 Chemolabeled Antibodies
    • 2.2.3 Immunotoxins

3. Mechanisms of Monoclonal Antibodies

  • 3.1 Tumor Antigens as Targets of Antibodies
  • 3.2 Development of Antibodies for Clinical Purposes
  • 3.3 Complement Dependent Cytotoxicity (CDC)
  • 3.4 Signal Transduction Changes

4. Need for Monoclonal Antibodies for Cancer Treatment

5. Cancer Monoclonal Antibodies Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Clinical Pipeline Insight

6. Cancer Monoclonal Antibodies Market Dynamics

  • 6.1 Favorable Parameters
  • 6.2 Challenges
  • 6.3 Future Growth Outlook

7. Cancer Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country

  • 7.1 Phase Unknown
  • 7.2 Research
  • 7.3 Preclinical
  • 7.4 Clinical
  • 7.5 Phase I
  • 7.6 Phase I/II
  • 7.7 Phase II
  • 7.8 Phase II/III
  • 7.9 Phase III
  • 7.10 Preregistration
  • 7.11 Registered

8. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country

9. Suspended & Discontinued Monoclonal Antibodies Pipeline by Phase, Indication, Company & Country

  • 9.1 No Development Reported
  • 9.2 Discontinued
  • 9.3 Market Withdrawal
  • 9.4 Suspended

10. Competitive Landscape

  • 10.1 Abbvie
  • 10.2 Amgen
  • 10.3 Bayer HealthCare
  • 10.4 Biogen Idec
  • 10.5 Eli Lilly
  • 10.6 Genmab
  • 10.7 Gilead Sciences
  • 10.8 GlaxoSmithKline
  • 10.9 Novartis
  • 10.10 Pfizer
  • 10.11 Roche
  • 10.12 Seattle Genetics
  • Figure 1-1: History of Development of Monoclonal Antibodies
  • Figure 1-2: Working of Monoclonal Antibodies
  • Figure 2-1: Types of Monoclonal Antibodies
  • Figure 5-1: Global Biologics Market Classification
  • Figure 5-2: Share of Monoclonal Antibodies in Biologics Market (%), 2013 & 2020
  • Figure 5-3: Global Market for Monoclonal Antibodies (US$ Billion), 2013-2020
  • Figure 5-4: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (%), 2014
  • Figure 5-5: Cancer Monoclonal Antibodies Therapy Pipeline by Phase (Number), 2014
  • Figure 5-6: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
  • Figure 5-7: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2014
  • Figure 5-8: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
  • Figure 5-9: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2014
  • Figure 5-10: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (%), 2014
  • Figure 5-11: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2014
Back to Top